NeoGenomics, Inc. (NEO) Bundle
An Overview of NeoGenomics, Inc. (NEO)
General Summary of NeoGenomics, Inc. (NEO)
NeoGenomics, Inc. is a specialized cancer-focused clinical laboratory and pharma services company headquartered in Fort Myers, Florida. Founded in 1996, the company provides cancer genetic testing, molecular diagnostic, and biomarker testing services.
Company Products and Services
- Oncology genetic testing services
- Precision medicine testing
- Pharmaceutical services
- Clinical trial testing solutions
Financial Performance Overview
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $751.1 million |
| Net Income | $13.6 million |
| Gross Margin | 47.3% |
Market Position and Industry Leadership
NeoGenomics operates as a leading precision oncology testing provider with capabilities in:
- Over 500 cancer testing centers nationwide
- Comprehensive molecular and biomarker testing
- Advanced pharmaceutical clinical trial services
| Key Operational Metrics | 2023 Performance |
|---|---|
| Total Tests Performed | Approximately 425,000 |
| Clinical Trials Supported | Over 200 active trials |
| Pharmaceutical Partnerships | 50+ active collaborations |
Mission Statement of NeoGenomics, Inc. (NEO)
Mission Statement of NeoGenomics, Inc. (NEO)
NeoGenomics, Inc. reported annual revenue of $672.4 million for the fiscal year 2023, with a focus on precision oncology diagnostics and testing services.
Core Components of Mission Statement
Precision Oncology Diagnostics
NeoGenomics specializes in cancer genetic testing with the following key metrics:
| Testing Category | Annual Volume | Market Segment |
|---|---|---|
| Molecular Testing | 525,000 tests | Oncology Diagnostics |
| Pathology Services | 375,000 cases | Clinical Diagnostics |
Key Strategic Focus Areas
- Clinical Trial Molecular Profiling: Supporting 250+ active clinical trials
- Precision Oncology Network: Collaborating with 3,500+ oncology practices
- Advanced Genomic Testing: Offering 50+ specialized cancer genetic panels
Technological Infrastructure
NeoGenomics operates with the following technological capabilities:
| Technology Platform | Capability | Annual Processing Capacity |
|---|---|---|
| Next-Generation Sequencing | Comprehensive Genomic Profiling | 750,000 genetic tests |
| Molecular Diagnostics | Precision Oncology Testing | 475,000 molecular analyses |
Research and Development Investment
R&D expenditure for 2023: $87.3 million, representing 13% of total revenue.
Market Position
- Market Share in Oncology Diagnostics: 14.5%
- Number of CLIA-Certified Laboratories: 12
- Geographic Coverage: United States, Europe
Vision Statement of NeoGenomics, Inc. (NEO)
NeoGenomics Vision Statement Components
Precision Oncology LeadershipNeoGenomics aims to be a global leader in precision oncology testing and services. As of 2024, the company operates with the following vision characteristics:
| Vision Dimension | Specific Focus |
|---|---|
| Market Position | Top 3 oncology testing provider in the United States |
| Annual Testing Volume | Over 1.5 million cancer tests per year |
| Geographic Reach | Operations in 12 laboratory locations |
NeoGenomics commits to advancing cancer diagnostics through cutting-edge technological platforms.
- Next-Generation Sequencing (NGS) capabilities
- Molecular profiling technologies
- Advanced genomic testing methodologies
| Clinical Objective | Metric |
|---|---|
| Precision Medicine Contribution | Supporting personalized treatment decisions for cancer patients |
| Research Collaborations | Active partnerships with 50+ research institutions |
| Clinical Trial Support | Genomic testing for 300+ active clinical trials |
NeoGenomics envisions transforming oncology diagnostics through comprehensive genomic insights.
- Expanding international testing capabilities
- Developing advanced diagnostic algorithms
- Integrating artificial intelligence in cancer diagnostics
Core Values of NeoGenomics, Inc. (NEO)
Core Values of NeoGenomics, Inc. (NEO)
Innovation and Scientific Excellence
NeoGenomics demonstrates commitment to innovation through substantial R&D investments of $33.4 million in 2023.
| R&D Metric | 2023 Value |
|---|---|
| Total R&D Expenditure | $33.4 million |
| New Test Developments | 12 novel genomic tests |
Patient-Centric Approach
NeoGenomics processed 1.8 million patient specimens in 2023, highlighting commitment to patient care.
- Turnaround time for test results: 2-3 business days
- Network of 29 laboratory locations
- Serving over 10,000 oncology practices
Operational Integrity
Financial performance demonstrates operational excellence.
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $526.1 million |
| Net Income | $12.3 million |
Collaborative Partnership
Strategic collaborations with pharmaceutical and research institutions.
- 12 active pharmaceutical research partnerships
- Over 50 clinical trial support agreements
- Participation in 37 research consortium networks
Technological Leadership
Advanced technological capabilities in genomic testing.
| Technology Metric | 2023 Performance |
|---|---|
| Molecular Testing Volume | 1.2 million tests |
| Next-Generation Sequencing Platforms | 7 advanced platforms |
NeoGenomics, Inc. (NEO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.